Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene

Gene Therapy

Volumn 6, Issue 10, 1999, Pages 1728-1733

  Colmenero, P ^a   Liljestrom P ^a,b   Jondal, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

P815; Semliki Forest virus; Tumor antigen; Viral vector

Indexed keywords

CANCER VACCINE; TUMOR REJECTION ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SEMLIKI FOREST ALPHAVIRUS; TUMOR IMMUNITY; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOGENS; FEMALE; GENE THERAPY; GENETIC VECTORS; MAST-CELL SARCOMA; METHYLCHOLANTHRENE; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032883094     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301004     Document Type: Article

References (54)

1. Fernandez N et al. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokin Cell Molec Ther 1998; 4: 53-65.
2. Pardoll DM. Cancer vaccines. Nature Med 1998; 4: 525-531.
3. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with nietastatic melanoma (see comments). Nature Med 1998; 4: 321-327.
4. Nestle FO et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells (see comments). Nature Med 1998; 4: 328-332.
5. Staveley OCK et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-1183.
6. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76: 287-299.
7. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994; 6: 722-727.
8. Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 1997; 12: 143-153.
9. Arienti F et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
10. Simons JW et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
11. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-693.
12. Van den Eynde B et al. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173: 1373-1384.
13. Amar-Costesec A et al. Identification and characterization of the tumor-specific P1A gene product. Biol Cell 1994; 81: 195-203.
14. Lethe B et al. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992; 22: 2283-2288.
15. van der Bruggen P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
16. Van Pel A et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995; 145: 229-250.
17. Uyttenhove C et al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer 1997; 70: 349-356.
18. Warnier G et al. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 1996; 67: 303-310.
19. Rosato A et al. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther 1997; 8: 1451-1458.
20. Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 1996; 70: 3781-3787.
21. Pugachev KV, Mason PW, Shope RE, Frey TK. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 1995; 212: 587-594.
22. Zhou X et al. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995; 92: 3009-3013.
23. Berglund P et al. Enhancing immune responses using suicidal DNA vaccines (see comments). Nature Biotechnol 1998; 16: 562-565.
24. Berglund P, Fleeton MN, Smerdou C, Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1998; 17: 508-518.
25. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Nature Biotechnol 1991; 9: 1356-1361.
26. Berglund P et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Bio/Technology 1993; 11: 916-920.
27. Berglund P et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retrovir 1997; 13: 1487-1495.
28. Mossman SP et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996; 70: 1953-1960.
29. Fleeton MN et al. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 1999; 80: 1189-1198.
30. Brichard VG et al. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur J Immunol 1995; 25: 664-671.
31. + cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tumor helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 1995; 25: 2797-2802.
32. + T cell response depending on the route of immunization. J Immunol 1998; 160: 5522-5529.
33. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 1996; 156: 1095-1100.
34. Uyttenhove C, Van Snick J, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med 1980; 152: 1175-1183.
35. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157: 1040-1052.
36. Pross HF, Eidinger D. Antigenic competition: a review of non-specific antigen-induced suppression. Adv Immunol 1974; 18: 133-168.
37. Heufler C et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-668.
38. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. Crit Rev Immunol 1998; 18: 87-98.
39. Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ. Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol 1997; 78: 1559-1563.
40. Carbone FR et al. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998; 19: 368-373.
41. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DMA immunization. Int Immunol 1997; 9: 1897-1906.
42. Inchauspe G et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997; 16: 185-195.
43. Kjerrulf M, Lowenadler B, Svanholm C, Lycke N. Tandem repeats of T helper epitopes enhance immunogenicity of fusion proteins by promoting processing and presentation. Molec Immunol 1997; 34: 599-608.
44. Lowenadler B et al. T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. Molec Immunol 1992; 29: 1185-1190.
45. Aichele P et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261-266.
46. Toes RE et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Prof Natl Acad Sci USA 1996; 93: 7855-7860.
47. Restifo NP. The new vaccines: building viruses that elicit anti-tumor immunity. Curr Opin Immunol 1996; 8: 658-663.
48. Jones L, Ristow S, Yilma T, Moss B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene (letter). Nature 1986; 319: 543.
49. Rooney JF et al. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 1988; 62: 1530-1534.
50. Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993; 11: 1154-1158.
51. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
52. Sjoberg EM, Suomalainen M, Garoff H. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Bio/Technology 1994; 12: 1127-1131.
53. Salminen A et al. Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry. J Cell Biol 1992; 116: 349-357.
54. Liljeström P, Garoff H. Expression of proteins using Semliki Forest virus vectors. In: Ausubel FM et al (eds). Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley Interscience: New York, 1994, pp 16.20.1-16.20.16.